This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
To the Editor:—
I read with great interest the report of the Council on Pharmacy and Chemistry on aminometradine (Mictine) published on page 116 of the Sept. 8 issue of The Journal. Of particular interest to me was the sentence in the fourth paragraph, which reads as follows: "Sufficient valid evidence is lacking, however, of the drug's usefulness in toxemia of pregnancy or premenstrual tension." I have no quarrel about the usefulness of the drug in premenstrual tension, since I have had no experimental work to substantiate this claim. However, I would like to take exception to the statement about its usefulness in toxemia. My associates and I have carried out a substantial amount of research regarding the metabolic effects of aminometradine in toxemia of pregnancy. The first report of Voskian and myself was published in the July issue of the Journal of Applied Physiology (9:111, 1956). The data
Assali NS. AMINOMETRADINE FOR TOXEMIA OF PREGNANCY. JAMA. 1956;162(16):1492. doi:10.1001/jama.1956.02970330064028